Department of Anesthesiology and Pain Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea.
Department of Anesthesiology and Pain Medicine, Gyeongsang National University College of Medicine, Jinju, Korea.
Korean J Anesthesiol. 2023 Jun;76(3):171-182. doi: 10.4097/kja.23031. Epub 2023 Jan 26.
Currently, lipid emulsion (LE) is widely used to treat local anesthetic systemic toxicity (LAST). LE also ameliorates intractable cardiovascular collapse caused by lipid-soluble non-local anesthetic drug toxicity. This review aims to provide the underlying mechanism of LE resuscitation in drug toxicity (including LAST) and a detailed description of LE treatment and to discuss further research directions. We searched for relevant articles using the following keywords: "local anesthetic systemic toxicity or LAST or toxicity or intoxication or poisoning" and "Intralipid or lipid emulsion". The underlying mechanisms of LE treatment can be classified into indirect and direct effects. One indirect effect known as the lipid shuttle is a commonly accepted mechanism of LE treatment. The lipid shuttle involves the absorption of highly lipid-soluble drugs (e.g., bupivacaine) from the heart and brain through the lipid phase, which are then delivered to the muscle, adipose tissue, and liver for storage and detoxification. The direct effects include inotropic effects, fatty acid supply, attenuation of mitochondrial dysfunction, glycogen synthase kinase-3β phosphorylation, and inhibition of nitric oxide. These mechanisms appear to act synergistically to treat drug toxicity. The recommended protocol for LE treatment of LAST is as follows: a bolus administration of 20% LE at 1.5 ml/kg over 2-3 min followed by 20% LE at 0.25 ml/kg/min. LAST most commonly occurs after intravenous administration of local anesthetics. However, non-local anesthetic drugs that cause drug toxicity are orally administered. Further studies are needed to determine the optimal dosing schedule of LE treatment for non-local anesthetic drug toxicity.
目前,脂乳剂(LE)被广泛用于治疗局部麻醉药全身毒性(LAST)。LE 还可以改善脂溶性非局部麻醉药毒性引起的难治性心血管崩溃。本综述旨在提供 LE 在药物毒性(包括 LAST)中的复苏机制的基本原理,并详细描述 LE 的治疗方法,并讨论进一步的研究方向。我们使用以下关键词搜索相关文章:“局部麻醉药全身毒性或 LAST 或毒性或中毒或中毒”和“Intralipid 或脂质乳剂”。LE 治疗的潜在机制可分为间接和直接影响。一种间接影响称为脂质穿梭,是 LE 治疗的一种公认机制。脂质穿梭涉及通过脂质相从心脏和大脑吸收高度脂溶性药物(例如布比卡因),然后将其递送至肌肉、脂肪组织和肝脏进行储存和解毒。直接作用包括正性肌力作用、脂肪酸供应、线粒体功能障碍减弱、糖原合酶激酶-3β磷酸化和一氧化氮抑制。这些机制似乎协同作用以治疗药物毒性。推荐的 LAST 用 LE 治疗方案如下:在 2-3 分钟内以 1.5ml/kg 的速度静脉注射 20%LE 作为负荷剂量,然后以 0.25ml/kg/min 的速度静脉注射 20%LE。LAST 最常发生在静脉内给予局部麻醉剂后。然而,引起药物毒性的非局部麻醉药是口服给予的。需要进一步研究确定 LE 治疗非局部麻醉药毒性的最佳剂量方案。